Anticipate generic drug launch
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pharmaceutical composition and method of treatment or prophylaxis of cardiac disorders|
|Abstract:||A pharmaceutical composition is disclosed, which contains a short-acting .beta.-blocking compound of the formula ##STR1## wherein R.sub.1 may be an alkyl, cycloalkyl, alkenyl, alkynyl, alkyl carboxymethyl, aryl carboxymethyl, aryl or aralkyl, A may be an alkylene or alkenylene, X may be independently amino, hydrogen, halogen, hydroxy, alkoxy, aryloxy, aralkyl, cyano, amido or trifluoromethyl, n is an integer from 1 to about 4, R may be an alkyl, propargyl, dimethylpropargyl or hydroxyalkyl; or a pharmaceutically acceptable salt thereof in a hydroalcoholic solution further containing a physiologically acceptable buffering agent, ethanol and a physiologically acceptable liquid polyhydric compound. A method for treatment or prophylaxis of cardiac disorders using the composition of the present invention is also disclosed.|
|Inventor(s):||Escobar; Agustin (Aquadilla, PR), Wagenknecht; Dietmar (Zion, IL), Malick; Ahmad W. (Edison, NJ)|
|Assignee:||E. I. Du Pont de Nemours and Company (Wilmington, DE)|
1. A pharmaceutical composition for parenteral administration comprising the .beta.-adrenergic compound ##STR7## or its pharmaceutically acceptable salts in an aqueous solution
comprising from about 5 to about 60% by volume ethanol; from about 5 to about 60% by volume propylene glycol, and from about 0.5 to about 2 molar physiologically acceptable buffering agent, said solution having a pH of from about 4.0 to about 6.0.
2. The composition of claim 1, wherein said solution comprises about 25% propylene glycol by volume, about 25% ethanol by volume and said buffering agent comprises sodium acetate and glacial acetic acid.
3. The composition of claim 2, wherein said pH is from about 4.5 to about 5.5.
4. A method for stabilizing a .beta.-adrenergic blocking compound having the formula ##STR8## or its pharmaceutically acceptable salts, comprising storing said compound in an aqueous solution comprising from about 0.1 to about 30% by weight of said compound, from about 0.05 to about 2 molar physiologically acceptable buffering agent, from about 5 to about 60% volume ethanol and from about 5 to about 60% by volume propylene glycol, said solution having a pH of from about 4.0 to about 6.0.
5. The method of claim 4, wherein said solution comprises about 25% by volume ethanol and about 25% by volume polypropylene glycol and said buffering agent comprises sodium acetate and glacial acetic acid.
6. The method of claim 5, wherein the pH of said solution is from about 4.5 to about 5.5.
7. A pharmaceutical composition for parenteral administration comprising from about 10 to about 25% by weight of a .beta.-adrenergic compound having the formula ##STR9## wherein R.sub.1 is ethyl or methyl and R is alkyl having from about 1 to about 6 carbon atoms; or its pharmaceutically acceptable salts in an aqueous solution further comprising from about 5 to about 60% by volume ethanol; from about 5 to about 60% by volume propylene glycol; and a physiologically acceptable buffer, said solution having a pH of from about 4.6 to about 5.4.
8. The composition of claim 7, wherein said buffer comprises sodium acetate.
9. The composition of claim 8, wherein said buffer further comprises glacial acetic acid.
10. The composition of claim 9, wherein said solution comprises about 25% by volume ethanol and about 25% by volume propylene glycol.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.